On April 20, 2026, BioCardia, Inc. announced a positive result from its clinical consultation with Japan’s PMDA regarding the CardiAMP® Cell Therapy, indicating sufficient evidence for market clearance. This filing is significant as it aligns the therapy for introduction in Japan and discusses the need for further studies.